PKI-166
PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM[1].
Product Specifications
CAS Number
187724-61-4
UNSPSC
12352005
Hazard Statement
H301
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pki-166.html
Purity
98.92
Solubility
DMSO : ≥ 125 mg/mL
Smiles
OC1=CC=C(C2=CC3=C(N=CN=C3N2)N[C@@H](C4=CC=CC=C4)C)C=C1
Molecular Formula
C20H18N4O
Molecular Weight
330.38
Precautions
H301
References & Citations
[1]Bruns CJ, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000 Jun 1;60 (11) :2926-35.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680100-500 1x 500 µL
CMV-p65 (CMV100), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
